公开(公告)号：US5763413A

公开(公告)日：1998-06-09

申请号：US505352

申请日：1995-08-30

Applicant: Masaaki Numata ,  Shigeki Nunomura ,  Shuji Fujita ,  Masami Iida ,  Akira Endo ,  Takayuki Ishii ,  Tomoya Ogawa ,  Mamoru Sugimoto ,  Ryoichi Osawa ,  Masamichi Fujita

Inventor： Masaaki Numata ,  Shigeki Nunomura ,  Shuji Fujita ,  Masami Iida ,  Akira Endo ,  Takayuki Ishii ,  Tomoya Ogawa ,  Mamoru Sugimoto ,  Ryoichi Osawa ,  Masamichi Fujita

IPC: C07H3/06 ,  C07H13/04 ,  C07H15/04 ,  C07H15/10 ,  A61K31/70 ,  C07H15/00 ,  C07H17/00

CPC classification number: C07H13/04 ,  C07H15/04 ,  C07H15/10 ,  C07H3/06

Abstract: A Lewis-associated compound, represented by general formula (I), a process for producing the same, and an anti-inflammatory, wherein R.sup.1 and R.sup.3 represent each hydrogen, m SO.sub.3 H or CH.sub.2 COOH; R.sup.2 represents hydrogen, SO.sub.3 H, CH.sub.2 COOH or N-acetyl-neutraminic acid residue; R.sup.4 represents hydrogen; R.sup.5 represents O-lower alkyl, O-lower alkenyl, O-ceramide residue, O-mannose residue, O-galactose residue or O-lactose residue; R.sup.6 represents acetylamine; and R.sup.7 and R.sup.8 represent each hydrogen. ##STR1##

Abstract translation: PCT No.PCT / JP94 / 00352 Sec。 371日期：1995年8月30日 102（e）日期1995年8月30日PCT 1994年3月4日PCT公布。 第WO94 / 20514号公报 1994年9月15日由通式（I）表示的路易斯相关化合物，其制造方法和抗炎剂，其中，R 1和R 3表示各自的氢，m SO 3 H或CH 2 COOH; R2表示氢，SO3H，CH2COOH或N-乙酰基 - 中甲酰赖氨酸残基; R4代表氢; R5表示O-低级烷基，O-低级烯基，O-神经酰胺残基，O-甘露糖残基，O-半乳糖残基或O-乳糖残基; R6表示乙酰胺; 并且R7和R8表示每个氢。 （一）

公开(公告)号：US5668115A

公开(公告)日：1997-09-16

申请号：US450699

申请日：1995-05-25

Applicant: Ryoichi Osawa ,  Isao Suda ,  Masaaki Numata ,  Mamoru Sugimoto ,  Kenkichi Tomita ,  Nobuyuki Kibushi ,  Takayuki Ishii ,  Naokazu Sugiyama ,  Makiko Kasano ,  Tae Yasunaga ,  Makoto Tanaka ,  Tomoya Ogawa ,  Mariko Ishii

Inventor： Ryoichi Osawa ,  Isao Suda ,  Masaaki Numata ,  Mamoru Sugimoto ,  Kenkichi Tomita ,  Nobuyuki Kibushi ,  Takayuki Ishii ,  Naokazu Sugiyama ,  Makiko Kasano ,  Tae Yasunaga ,  Makoto Tanaka ,  Tomoya Ogawa ,  Mariko Ishii

IPC: C12P19/04 ,  A61K31/70 ,  A61K31/715 ,  A61P7/02 ,  A61P13/02 ,  A61P15/00 ,  A61P37/08 ,  C07H13/04 ,  C12R1/01

CPC classification number: A61K31/715 ,  A61K31/70 ,  A61K31/7012 ,  A61K31/7016 ,  A61K31/702 ,  C07H13/04 ,  Y10S514/825 ,  Y10S514/885

Abstract: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.

Abstract translation: 一种抗炎药，其包含选自科洛芬酸，聚洛米酸的部分水解产物和其药学上可接受的盐中的至少一种化合物作为有效成分。 该药用作肾脏疾病的药物，用于肝炎的药物，免疫调节剂和抑制嗜中性粒细胞趋化性的药物。

公开(公告)号：US5529854A

公开(公告)日：1996-06-25

申请号：US231866

申请日：1994-04-25

Applicant: Tatsuya Shimoda ,  Satoshi Shimokawato ,  Shin Funada ,  Mamoru Sugimoto ,  Akira Aoyama ,  Satoshi Nebashi

Inventor： Tatsuya Shimoda ,  Satoshi Shimokawato ,  Shin Funada ,  Mamoru Sugimoto ,  Akira Aoyama ,  Satoshi Nebashi

IPC: G11B11/105 ,  G11B5/66 ,  C23C14/00 ,  G11B11/00 ,  G11C13/06

CPC classification number: G11B11/10582 ,  G11B11/10586 ,  Y10S428/90

Abstract: A magnetic recording film and a magneto-optic recording system utilizing films. The film includes light and heavy rare earth elements and transition metal elements. The system can include dielectric layers and low magnetic coercivity layers in addition to the recording layer.

Abstract translation: 磁记录膜和利用膜的磁光记录系统。 该薄膜包括轻和重稀土元素和过渡金属元素。 该系统除了记录层之外还可以包括电介质层和低磁矫顽力层。

公开(公告)号：US5504735A

公开(公告)日：1996-04-02

申请号：US163604

申请日：1993-12-06

Applicant: Tsutomu Ota ,  Mamoru Sugimoto ,  Yasuto Nose ,  Hidetoshi Yoshitaki ,  Tatsuro Higashi ,  Takashi Hayashi

Inventor： Tsutomu Ota ,  Mamoru Sugimoto ,  Yasuto Nose ,  Hidetoshi Yoshitaki ,  Tatsuro Higashi ,  Takashi Hayashi

IPC: G11B7/24 ,  G11B23/00 ,  G11B3/70

CPC classification number: G11B23/0035 ,  G11B7/24

Abstract: An information recording disk formed from two substrates with a stepped central opening for receiving a hub within the stepped recess of at least one of the substrates is provided. In one embodiment, the central aperture of the first substrate is larger than the central aperture of the second substrate to form the stepped recess. In another embodiment, at least one substrate has a stepped surface defining a central aperture and a hub structure is mounted within this stepped recess to reduce overall thickness of the disk.

Abstract translation: 提供了一种信息记录盘，其由具有台阶中心开口的两个基板形成，用于在至少一个基板的台阶凹槽内容纳轮毂。 在一个实施例中，第一基板的中心孔径大于第二基板的中心孔径以形成台阶凹槽。 在另一个实施例中，至少一个基板具有限定中心孔的台阶表面，并且毂结构安装在该阶梯形凹槽内以减小盘的整体厚度。

公开(公告)号：US5393742A

公开(公告)日：1995-02-28

申请号：US109614

申请日：1993-08-19

Applicant: Takayuki Ishii ,  Makiko Kasano ,  Tae Yasunaga ,  Mariko Ishii ,  Mamoru Sugimoto ,  Kenkichi Tomita ,  Takeshi Miyata ,  Makoto Tanaka

Inventor： Takayuki Ishii ,  Makiko Kasano ,  Tae Yasunaga ,  Mariko Ishii ,  Mamoru Sugimoto ,  Kenkichi Tomita ,  Takeshi Miyata ,  Makoto Tanaka

IPC: A61K31/70

CPC classification number: A61K31/7004 ,  A61K31/70

Abstract: A preparation is useful for treating renal disease, such as nephritis and especially nephrosis (nephrotic syndrome), which comprises an effective amount of N-acetylneuraminic acid shown by the formula ##STR1## wherein, when n is 1, Z represents hydrogens, lithium, potassium, sodium, ammonium or organic ammonium, and when n is 2, Z represents calcium, barium or magnesium, and a pharmacologically acceptable carrier.

Abstract translation: 一种制剂可用于治疗肾脏疾病，例如肾炎，特别是肾病（肾病综合征），其包含有效量的由马来酰亚胺，锂，钾，钠，铵或有机铵显示的N-乙酰神经氨酸，当n为 2，Z表示钙，钡或镁，以及药理学上可接受的载体。

公开(公告)号：US5264567A

公开(公告)日：1993-11-23

申请号：US13993

申请日：1993-02-05

Applicant: Masaaki Numata ,  Mamoru Sugimoto ,  Shuji Fujita ,  Masanori Kobayashiu ,  Kenkichi Tomita ,  Makoto Tanaka ,  Tomoya Ogawa

Inventor： Masaaki Numata ,  Mamoru Sugimoto ,  Shuji Fujita ,  Masanori Kobayashiu ,  Kenkichi Tomita ,  Makoto Tanaka ,  Tomoya Ogawa

IPC: C07H13/04 ,  C07H15/04 ,  C07H15/10 ,  C07H15/14 ,  C07G17/00 ,  A01N43/04 ,  C07H1/00 ,  C07H5/04

CPC classification number: C07H13/04 ,  C07H15/04 ,  C07H15/10 ,  C07H15/14

Abstract: GM.sub.3 analogous compound (I) below: ##STR1## wherein one of R.sup.2 and R.sup.3 represents a neuramic acid group represented by general formula (V): ##STR2## R.sup.5 represents ##STR3## or hydrogen; R.sup.6 represents hydrogen or a ceramide group represented by general formula (VI): ##STR4##

Abstract translation: GM3类似化合物（I）：其中R2和R3之一表示由通式（V）表示的神经酰胺酸基团：其中R5表示氢或氢; R6表示氢或由通式（VI）表示的神经酰胺基团：（VI）

公开(公告)号：US5101026A

公开(公告)日：1992-03-31

申请号：US82289

申请日：1987-08-06

Applicant: Tomoya Ogawa ,  Mamoru Sugimoto ,  Masaaki Numata ,  Masayoshi Ito ,  Yoshiyasu Shitori ,  Shigeki Nunomura

Inventor： Tomoya Ogawa ,  Mamoru Sugimoto ,  Masaaki Numata ,  Masayoshi Ito ,  Yoshiyasu Shitori ,  Shigeki Nunomura

IPC: C07H3/06 ,  C07H15/10

CPC classification number: C07H15/10 ,  C07H3/06

Abstract: The present invention relates to ganglioside related compounds having, for example, the following formula: ##STR1## where R.sub.1 represents H or COCH.sub.3 (hereinafter abbreviated to "AC"); R.sub.2 represents H or CH.sub.3 ; and R.sub.3 represents --OH, ##STR2## These ganglioside related compounds are useful as membrane receptors, tumor markers, cell growth controlling substances, etc., and useful for immunotherapy for cancer, etc.

公开(公告)号：US4921948A

公开(公告)日：1990-05-01

申请号：US319064

申请日：1989-03-06

Applicant: Shoji Yoshimura ,  Yuzi Matsuzaki ,  Mamoru Sugimoto ,  Masayoshi Ito ,  Tomoya Ogawa

Inventor： Shoji Yoshimura ,  Yuzi Matsuzaki ,  Mamoru Sugimoto ,  Masayoshi Ito ,  Tomoya Ogawa

IPC: C07H15/04 ,  A61K31/70 ,  A61K31/7028 ,  A61P25/00 ,  C07H15/06

CPC classification number: C07H15/06

Abstract: The present application discloses a new sialosyl glyceride having the following formula, which compound is useful as a remedy for nervous diseases, has an excellent compatability with the living bodies, and is easily producible. ##STR1## wherein R.sup.1 represents a hydrogen atom or XCH.sub.2 CO-- (X being a halogen atom), R.sup.2 represents an alkali metal, a hydrogen atom or a lower alkyl group, R.sup.3 represents a hydrogen atom or --CO(CH.sub.2)mCH.sub.3, R.sup.4 represents --CO(CH.sub.2)mCH.sub.3 amd m and n each represents a number of 0 to 30.

公开(公告)号：US4801499A

公开(公告)日：1989-01-31

申请号：US819659

申请日：1986-01-17

Applicant: Akira Aoyama ,  Shigeru Kogure ,  Mamoru Sugimoto

Inventor： Akira Aoyama ,  Shigeru Kogure ,  Mamoru Sugimoto

IPC: G11B7/257 ,  G11B7/26 ,  G11B11/105 ,  G11B7/24

CPC classification number: G11B7/26 ,  G11B11/10582 ,  G11B7/2578 ,  G11B2007/25706 ,  G11B2007/25708 ,  G11B2007/2571 ,  G11B2007/25711 ,  G11B2007/25713 ,  G11B2007/25716 ,  G11B7/2531 ,  G11B7/2533 ,  G11B7/2534 ,  G11B7/2585 ,  Y10S428/90 ,  Y10T428/265

Abstract: A magneto-optic recording medium including a transparent substrate and a non-oxide dielectric layer formed thereon is provided. The dielectric layer includes a first dielectric material of the type which exhibits cracks running in a generally radial direction when deposited on a surface and which is designated dielectric Group A and a second dielectric material which exhibits cracks running in a generally tangential direction when deposited on a surface and which is designated dielectric Group B. The dielectric layer may be separate layers or a mixture of the two dielectric materials.

Abstract translation: 提供了包括形成在其上的透明基板和非氧化物介电层的磁光记录介质。 电介质层包括第一电介质材料，该电介质材料当沉积在表面上时呈现出沿大致径向方向的裂纹，并且被指定为电介质组A和第二电介质材料，其在沉积在 表面，并且其被指定为电介质组B.电介质层可以是分离的层或两种介电材料的混合物。

公开(公告)号：US4418012A

公开(公告)日：1983-11-29

申请号：US300415

申请日：1981-09-09

Applicant: Setsuro Fujii ,  Mamoru Sugimoto ,  Takashi Yaegashi

Inventor： Setsuro Fujii ,  Mamoru Sugimoto ,  Takashi Yaegashi

IPC: C07K5/08 ,  C07K5/083 ,  C12Q1/34 ,  C12Q1/37 ,  C12Q1/56 ,  C07C103/52

CPC classification number: C07K5/0808 ,  C12Q1/34 ,  C12Q1/56 ,  C12Q2334/30 ,  G01N2333/974 ,  Y02P20/55

Abstract: A leucylalanyarginine derivative represented by the formula, ##STR1## wherein R.sub.1 represents hydrogen or an amino-protecting group; R.sub.2 and R.sub.3 represent hydrogen or guanidino-protecting groups; and R.sub.4 represents naphthyl. The above compound is useful as an excellent substrate for various enzymes, such as trypsin, plasmin, kallikrein, urokinase, Cl-esterase and the like. Accordingly, the activity of enzymes can be measured by use of said compound as a substrate.

Abstract translation: 由下式表示的亮氨酰基精氨酸衍生物，其中R 1表示氢或氨基保护基; R2和R3表示氢或胍基保护基; 并且R 4表示萘基。 上述化合物可用作各种酶的优异底物，例如胰蛋白酶，纤溶酶，激肽释放酶，尿激酶，C1-酯酶等。 因此，可以通过使用所述化合物作为底物来测量酶的活性。